chronic myeloproliferative disorder: A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
478 |
4. Check minimum number of eventsNone |
478 |
5. Include endpointsNone |
478 |
6. Filter based on genotype QC (FinnGen only) |
464 |
Control definitions (FinnGen only)
- Control exclude
- MYELOPROF
Extra metadata
- First used in FinnGen datafreeze
- DF2, additional
Similar endpoints
↥List of similar endpoints to
Chronic myeloproliferative disease
based on the number of shared cases.
Similar with more cases:
- Myeloproliferative diseases
- Liquid cancers, helper endpoint
- Neoplasms
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2801 | 1352 | 1414 |
| Only index persons | 2074 | 1031 | 1043 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.04 |
| Only index persons | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 70.78 | 71.37 | 70.24 |
| Only index persons | 69.56 | 69.80 | 69.34 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 464 | 210 | 254 |
| Unadjusted period prevalence (%) | 0.10 | 0.07 | 0.12 |
| Median age at first event (years) | 67.77 | 66.29 | 68.99 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 478
- Matched controls
- 4780
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
+∞
307.7
478
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
148.2
307.7
370
108
L01XX05
ATC
hydroxycarbamide; oral
2820.6
301.9
260
*
XW000
NOMESCO Finland
Bone marrow biopsy
30.1
259.2
195
107
9961/3-C42.1
ICD-O-3
Primary myelofibrosis of bone marrow
3136.6
206.9
185
*
D45
ICD-10 Finland
Polycythaemia vera
2712.1
189.8
171
*
D47.3
ICD-10 Finland
Essential (haemorrhagic) thrombocythaemia
+∞
163.1
147
*
174
Kela drug reimbursment
Ruxolitinib
+∞
143.1
130
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
57.2
141.5
81
17
B03XA02
ATC
darbepoetin alfa; parenteral
26.9
137.1
99
46
374
Kela drug reimbursment
Ruxolitinib
+∞
129.2
118
*
D75.2
ICD-10 Finland
Essential thrombocytosis
+∞
123.4
113
*
L01EJ01
ATC
ruxolitinib; oral
+∞
117.7
108
*
WW500
NOMESCO Finland
Blood transfusion
12.8
102.9
111
110
M04AA01
ATC
allopurinol; systemic
7.2
98.2
212
479
9950/3-C42.1
ICD-O-3
Polycythemia vera of bone marrow
+∞
88.3
82
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.5
77.3
166
364
L01XE18
ATC
[U] ruxolitinib
+∞
77.2
72
*
9962/3-C42.1
ICD-O-3
Essential thrombocythemia of bone marrow
+∞
75.0
70
*
L03AB05
ATC
interferon alfa-2b; parenteral
194.2
65.9
67
*
L01XX35
ATC
anagrelide; oral
+∞
62.9
59
*
TPH00
NOMESCO Finland
Phlebotomy
630.0
57.9
56
*
B03XA01
ATC
erythropoietin; parenteral
24.2
52.3
38
17
9960/3-C42.1
ICD-O-3
Myeloproliferative neoplasm, NOS, of bone marrow
+∞
52.0
49
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.4
46.5
109
250
SPAT1074
SPAT
Venesection
78.4
38.6
43
6
D64.9
ICD-10 Finland
Anaemia, unspecified
4.1
34.9
118
356
212
Kela drug reimbursment
Gout
9.6
32.0
39
44
R50.9
ICD-10 Finland
Fever, unspecified
3.7
31.7
127
429
B99
ICPC
Blood/lymph/spleen disease other
75.2
31.3
35
5
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
44.4
30.4
37
9
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
57.0
27.5
32
6
L03AB04
ATC
interferon alfa-2a; parenteral
102.7
27.0
29
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.3
23.4
107
387
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
38.5
23.3
29
8
R04.0
ICD-10 Finland
Epistaxis
3.7
21.4
77
238
Z51.5
ICD-10 Finland
Palliative care
3.5
21.1
81
261
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
31.7
20.8
27
9
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
30.4
19.8
26
9
306
Kela drug reimbursment
Erythropoietin and darbepoetin
48.2
19.4
23
5
D46.7
ICD-10 Finland
Other myelodysplastic syndromes
27.4
19.3
26
10
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.4
18.8
190
1021
B74
ICPC
Malignant neoplasm blood other
+∞
17.8
17
*
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
6.9
17.7
28
43
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
3.8
16.8
54
154
C03CA01
ATC
furosemide; systemic
2.2
16.2
224
1355
127
Kela drug reimbursment
Transplant complication
12.9
16.1
28
23
D47.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue, unspecified
27.4
15.7
21
8
B82
ICPC
Anaemia other/unspecified
5.3
15.5
32
64
9861/3-C42.1
ICD-O-3
Acute myeloid leukemia, NOS, of bone marrow
37.3
14.5
18
5
D50.0
ICD-10 Finland
Iron deficiency anaemia secondary to blood loss (chronic)
4.7
14.5
34
76
M10.9
ICD-10 Finland
Gout, unspecified
3.1
14.3
64
225
D46.9
ICD-10 Finland
Myelodysplastic syndrome, unspecified
23.1
14.3
20
9
B01AC14
ATC
[U] anagrelide
+∞
13.6
13
*
XX7BT
NOMESCO Finland
Radioactive phosphorus therapy
+∞
13.6
13
*
SPAT1088
SPAT
Blood transfusion
26.6
13.5
18
7
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.1
13.4
274
1881
A05AA02
ATC
ursodeoxycholic acid; oral
9.7
12.6
25
27
D73.5
ICD-10 Finland
Infarction of spleen
133.4
12.5
13
*
XW4XT
NOMESCO Finland
Biopsy of other inner organ with radiological guidance guidance
38.6
12.3
15
*
L03AA04, ,
ATC
27.5
12.1
16
6
B28
ICPC
Limited function/disability (B)
27.5
12.1
16
6
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.6
11.9
78
336
R16.1
ICD-10 Finland
Splenomegaly, not elsewhere classified
66.6
11.7
13
*
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
66.6
11.7
13
*
L04AD01
ATC
ciclosporin; systemic
9.6
11.6
23
25
D47.2
ICD-10 Finland
Monoclonal gammopathy of undetermined significance (MGUS)
8.7
11.4
24
29
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.6
11.1
68
283
JN3AD
NOMESCO Finland
Abdominal CT examination
2.5
11.0
73
316
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
3.3
11.0
42
134
D73.1
ICD-10 Finland
Hypersplenism
61.4
10.7
12
*
H02AB06
ATC
prednisolone; systemic
1.9
10.7
252
1768
L03AA02
ATC
filgrastim; parenteral
4.2
10.6
29
73
C94.5
ICD-10 Finland
Acute myelofibrosis
+∞
10.5
10
*
C90.0
ICD-10 Finland
Multiple myeloma
9.1
10.4
21
24
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.0
10.3
161
983
B01AB05
ATC
enoxaparin; parenteral
1.9
9.8
183
1181
J05AB11
ATC
valaciclovir; oral
2.3
9.8
87
429
D46.0
ICD-10 Finland
Refractory anaemia without ring sideroblasts, so stated
102.0
9.4
10
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
2.7
9.4
53
211
2384A
ICD-9 Finland
Neoplasm of uncertain behaviour of other and unspecified sites and tissues, Polycythaemia vera
+∞
9.4
9
*
I81
ICD-10 Finland
Portal vein thrombosis
16.0
9.1
14
9
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
1.9
8.8
148
918
TPH00, ,
SPAT
50.9
8.7
10
*
I50.9
ICD-10 Finland
Heart failure, unspecified
2.0
8.7
104
574
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
3.5
8.5
29
86
V03AC03
ATC
deferasirox; oral
91.6
8.4
9
*
D47.0
ICD-10 Finland
Histiocytic and mast cell tumours of uncertain and unknown behaviour
91.6
8.4
9
*
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
+∞
8.4
8
*
R79.9
ICD-10 Finland
Abnormal finding of blood chemistry, unspecified
14.8
8.2
13
9
I85.9
ICD-10 Finland
Oesophageal varices without bleeding
9.2
8.1
16
18
L29.8
ICD-10 Finland
Other pruritus
9.2
8.1
16
18
A46
ICD-10 Finland
Erysipelas
2.1
8.1
89
476
A02BC02
ATC
pantoprazole; systemic
1.8
7.8
340
2759
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
2.6
7.7
47
195
J01MA12
ATC
levofloxacin; systemic
1.9
7.5
110
648
WW306
NOMESCO Finland
Transfer of stem cells from foreign registered donator
81.3
7.4
8
*
Y84.8
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
11.1
7.3
13
12
C10AA07
ATC
rosuvastatin; oral
0.5
7.3
61
1141
2387X
ICD-9 Finland
Neoplasm of uncertain behaviour of other and unspecified sites and tissues, Other lymphatic and haematopoietic tissues[STATUS LYMPHO- ET MYELOPROLIFERATIVUS NUD]
+∞
7.3
7
*
WW200
NOMESCO Finland
Immunization
4.3
7.1
18
43
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
3.5
7.1
24
71
D75.1
ICD-10 Finland
Secondary polycythaemia
14.0
6.9
11
8
ZX120
NOMESCO Finland
Intravenous
2.2
6.9
58
278
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
6.3
6.8
17
28
N02AA05
ATC
oxycodone; systemic
1.8
6.8
111
676
D47.7
ICD-10 Finland
Other specified neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue
40.6
6.8
8
*
YJ1AD
NOMESCO Finland
CT examination of abdomen for dose design of radiotherapy
22.9
6.7
9
*
XQ848
NOMESCO Finland
Dermatological photography
3.8
6.4
19
51
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
1.8
6.4
112
696
E78.0
ICD-10 Finland
Pure hypercholesterolaemia
0.4
6.3
31
719
J05AX18
ATC
letermovir; oral
+∞
6.3
6
*
D75.0
ICD-10 Finland
Familial erythrocytosis
+∞
6.3
6
*
I82.0
ICD-10 Finland
Budd-Chiari syndrome
+∞
6.3
6
*
L04AX02
ATC
thalidomide; oral
27.1
6.2
8
*
ZXD00
NOMESCO Finland
Emergency procedure
3.6
6.2
20
57
B04
ICPC
Blood symptom/complaint
12.7
6.1
10
8
Z01.8
ICD-10 Finland
Other specified special examinations
1.8
6.0
113
715
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
340
482
21.97
267.25
18.0
4.1
456.10
245.33
u/l
32.36
333
452
151
67
32.48
216.33
1.5
1.2
74.79
31.05
u/l
1.60
135
57
149
76
28.03
201.60
1.9
1.6
—
—
—
0
0
282
556
10.93
158.76
7.0
2.6
2.36
1.82
%
9.36
261
506
245
416
11.03
156.14
7.7
2.8
86.16
69.53
e9/l
6.40
201
339
215
330
11.02
147.86
18.2
4.2
2.55
0.86
%
11.20
174
128
106
63
21.33
132.00
15.4
3.7
2.52
1.00
%
4.48
97
56
186
291
9.83
123.86
19.0
4.2
1.83
0.46
%
16.31
151
106
185
312
9.04
114.78
18.2
4.3
0.35
0.15
%
2.49
146
110
149
224
9.21
100.99
2.4
1.9
0.85
1.48
g/l
13.47
131
201
236
597
6.83
97.10
3.1
2.4
25.20
22.23
%
1.79
198
512
239
626
6.64
94.33
3.0
2.3
2.22
2.29
g/l
0.93
227
572
108
121
11.24
91.54
2.3
1.7
—
—
—
0
0
245
679
6.35
90.27
3.1
2.4
13.51
12.61
umol/l
1.03
233
627
67
34
22.76
88.54
1.2
1.1
—
—
—
0
0
81
76
12.63
77.03
10.4
7.1
1192.90
211.46
iu/ml
—
10
13
294
1089
5.42
73.92
7.3
2.9
2107.51
9993.90
umol/l
3.25
273
925
58
44
14.86
62.42
17.7
3.2
63.89
55.58
%
1.13
47
38
65
63
11.78
60.11
4.0
3.8
519.60
3259.63
u/ml
—
5
8
366
1818
5.32
58.67
24.0
5.4
2.17
2.89
%
8.38
355
1698
368
1850
5.30
57.67
24.4
5.6
20.25
26.47
%
20.36
355
1732
350
1823
4.44
48.86
19.3
5.4
64.03
58.04
%
12.07
335
1708
55
62
9.89
45.45
9.8
2.9
66.55
58.97
%
2.36
55
62
317
1613
3.87
44.04
5.4
2.6
356.71
150.54
ug/l
2.98
305
1458
52
59
9.77
42.71
4.8
2.2
31.02
32.78
pg
1.65
52
59
248
1104
3.59
41.85
2.8
2.1
5.42
3.16
mg/l
6.74
225
930
35
26
14.45
37.75
10.6
3.9
—
—
—
0
0
107
295
4.38
35.83
2.9
2.6
9.84
10.51
g/l
0.60
97
265
358
2164
3.61
34.11
18.4
6.5
14.04
12.00
umol/l
1.20
350
2064
32
26
13.12
32.69
1.6
1.5
—
—
—
0
0
32
26
13.12
32.69
1.6
1.5
—
—
—
0
0
117
377
3.79
31.26
2.6
3.2
66.01
66.08
g/l
0.03
107
343
362
2270
3.45
31.03
30.8
8.7
7.28
4.18
e9/l
8.44
347
2000
148
568
3.33
30.01
5.8
5.5
1.10
1.01
mmol/l
3.01
137
514
164
695
3.07
27.82
5.7
3.4
0.82
0.81
mmol/l
0.62
156
642
166
713
3.03
27.44
3.2
1.9
32.32
29.60
s
5.88
159
687
39
58
7.23
25.44
1.4
1.3
—
—
—
0
0
43
74
6.29
24.44
3.7
1.9
—
—
—
0
0
330
2127
2.78
23.72
11.8
7.2
1.20
1.21
mmol/l
3.89
268
1826
49
100
5.35
23.28
3.6
1.8
—
—
—
0
0
48
97
5.39
23.05
4.0
1.8
—
—
—
0
0
206
1105
2.52
20.98
2.1
1.6
18.14
20.75
nmol/l
1.73
194
925
39
72
5.81
20.60
4.0
1.7
—
—
—
0
0
39
72
5.81
20.60
4.0
1.7
—
—
—
0
0
115
479
2.84
19.32
8.2
2.8
6.68
8.90
umol/l
1.28
107
431
33
55
6.37
19.29
1.5
1.2
266.71
313.18
u/ml
0.20
17
28
153
738
2.58
19.22
3.0
1.9
—
—
—
0
0
174
897
2.48
18.92
2.0
1.7
1265.82
1171.53
nmol/l
0.60
130
670
89
330
3.09
18.37
3.6
3.6
1.20
1.23
mmol/l
3.70
77
283
88
326
3.08
18.18
2.7
1.6
—
—
—
0
0
287
1865
2.35
18.12
9.4
4.8
35.70
35.06
g/l
1.13
272
1733
31
54
6.07
17.34
1.3
1.3
—
—
—
0
0
185
1017
2.34
17.07
7.3
4.1
74.40
87.29
%
8.76
175
995
294
1966
2.29
16.84
10.0
6.2
1.20
1.21
mmol/l
1.43
275
1757
278
1822
2.26
16.65
2.8
2.1
85.80
94.79
pmol/l
2.58
188
934
59
180
3.60
16.61
2.9
2.6
—
—
—
0
0
30
54
5.86
16.22
4.6
1.8
—
—
—
0
0
30
57
5.55
15.33
4.7
1.7
—
—
—
0
0
26
46
5.92
14.29
5.0
1.7
—
—
—
0
0
26
46
5.92
14.29
5.0
1.7
—
—
—
0
0
26
46
5.92
14.29
5.0
1.7
—
—
—
0
0
47
140
3.61
13.67
4.8
3.9
1.21
2.46
ratio
—
6
13
47
143
3.54
13.24
4.9
4.0
108.08
101.37
mg/l
0.03
38
117
47
143
3.54
13.24
4.9
4.0
43.16
51.11
mg/l
0.13
39
117
393
3115
2.47
13.17
25.4
7.7
96.53
79.79
u/l
6.60
383
2898
90
411
2.47
12.16
2.0
2.2
0.20
0.21
g/l
0.32
78
386
268
1871
1.98
12.01
10.5
2.7
—
—
—
0
0
19
13
15.16
11.88
12.3
5.0
61.76
47.88
%
0.81
19
13
103
514
2.28
11.34
2.0
1.9
—
—
—
0
0
150
869
2.06
11.29
2.2
1.7
1.38
1.30
mg/l
0.13
117
682
31
79
4.13
11.20
2.4
2.6
12.87
15.47
%
1.67
15
40
21
21
10.40
11.11
5.9
1.8
—
—
—
0
0
21
21
10.40
11.11
5.9
1.8
—
—
—
0
0
102
514
2.25
10.94
2.1
1.9
—
—
—
0
0
22
25
9.17
10.88
5.7
1.7
—
—
—
0
0
22
25
9.17
10.88
5.7
1.7
—
—
—
0
0
21
22
9.93
10.85
5.9
1.8
—
—
—
0
0
10
0
+∞
10.45
1.1
0.0
—
—
—
0
0
19
18
10.94
10.36
1.5
1.7
2025.00
974.56
u/ml
0.54
19
18
21
43
5.06
9.87
1.4
1.8
—
—
—
0
0
22
47
4.86
9.86
3.3
2.5
—
—
—
0
0
22
30
7.63
9.81
1.2
3.7
30.43
42.67
%
—
7
18
40
135
3.14
9.55
1.7
1.2
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
43
153
2.99
9.39
3.7
2.4
0.35
0.36
u/ml
0.04
26
78
87
437
2.21
9.31
4.1
3.4
—
—
—
0
0
20
27
7.68
9.02
1.1
1.6
—
—
—
0
0
283
2137
1.79
8.75
23.4
16.4
1.48
1.33
inr
1.96
110
566
15
13
11.87
8.62
8.7
1.3
—
—
—
0
0
24
62
4.02
8.52
1.5
1.7
—
—
—
0
0
8
0
+∞
8.35
5.4
0.0
—
—
—
0
0
13
9
14.80
8.24
1.0
1.2
—
—
—
0
0
11
5
22.46
8.05
1.1
1.0
87.45
113.00
%
—
11
5
209
1470
1.75
8.04
3.3
3.1
2959.54
1475.72
ng/l
2.66
189
1279
19
43
4.56
7.96
1.5
1.9
—
—
—
0
0
25
71
3.66
7.80
1.8
1.6
—
—
—
0
0
16
20
8.24
7.65
1.6
2.3
—
—
—
0
0
12
9
13.64
7.42
1.9
1.4
—
—
—
0
0
309
2465
1.72
7.20
8.1
5.1
6.67
6.82
mmol/l
0.67
299
2328
31
109
2.97
6.93
1.4
1.5
2.17
0.12
iu/ml
—
5
28
152
1011
1.74
6.91
11.0
2.4
—
—
—
0
0
177
1229
1.70
6.88
5.7
3.3
33.91
31.63
u/l
0.78
170
1168
40
162
2.60
6.88
3.5
2.9
—
—
—
0
0
69
357
2.09
6.78
2.1
1.9
407.90
383.87
nmol/l
0.34
63
321
13
15
8.87
6.59
1.5
1.3
—
—
—
0
0
13
15
8.87
6.59
1.2
1.1
160.87
115.20
u/l
0.64
13
15
13
15
8.87
6.59
1.2
1.1
60.17
44.87
u/l
0.36
13
15
10
7
14.55
6.42
1.1
3.4
—
—
—
0
0
20
58
3.56
6.07
1.6
1.7
—
—
—
0
0
27
96
2.92
5.93
1.1
1.2
—
—
—
0
0
15
29
5.30
5.43
4.7
1.8
—
—
—
0
0
17
48
3.64
5.37
1.9
1.6
—
—
—
0
0
17
48
3.64
5.37
1.9
1.6
—
—
—
0
0
19
58
3.37
5.36
4.8
1.4
—
—
—
0
0
19
58
3.37
5.36
4.8
1.4
—
—
—
0
0
19
58
3.37
5.36
4.8
1.4
—
—
—
0
0
10
11
9.26
5.31
1.0
1.1
—
—
—
0
0
12
18
6.81
5.28
1.2
1.2
—
—
—
0
0
10
12
8.48
5.08
1.2
1.4
—
—
—
0
0
14
28
5.12
4.98
2.6
1.3
—
—
—
0
0
55
294
1.98
4.94
1.8
1.7
—
—
—
0
0
18
56
3.30
4.94
5.0
1.4
—
—
—
0
0
174
1295
1.54
4.71
3.2
2.5
49.15
59.99
u/l
2.07
161
1196
18
58
3.19
4.68
5.0
1.4
—
—
—
0
0
12
22
5.57
4.63
2.9
1.2
—
—
—
0
0
12
22
5.57
4.63
2.9
1.2
—
—
—
0
0
19
64
3.05
4.60
1.9
1.6
—
—
—
0
0
7
5
14.18
4.59
1.1
1.6
—
—
—
0
0
18
59
3.13
4.56
5.0
1.4
—
—
—
0
0
36
170
2.21
4.47
2.6
1.7
—
—
—
0
0
342
2956
1.55
4.45
6.3
4.2
16.74
13.64
mm/h
2.01
316
2678
52
283
1.94
4.45
5.3
3.9
1.01
2.03
mmol/l
1.16
35
219
218
1725
1.48
4.31
4.7
4.1
34.53
58.25
ng/l
0.67
177
1327
11
20
5.60
4.31
12.2
3.4
422.73
208.50
u/l
2.73
11
20
17
56
3.11
4.28
1.7
1.7
—
—
—
0
0
11
22
5.09
4.02
1.3
1.4
—
—
—
0
0
37
185
2.08
4.00
5.9
1.9
—
—
—
0
0
10
18
5.65
3.99
1.3
1.1
—
—
—
0
0
172
1318
1.48
3.90
4.1
3.4
28.85
115.43
e6/l
1.05
143
1025
12
28
4.37
3.84
2.9
1.3
—
—
—
0
0
13
33
4.02
3.82
1.5
1.1
—
—
—
0
0
7
8
8.86
3.78
1.7
1.5
—
—
—
0
0
6
5
12.13
3.77
1.2
1.0
—
—
—
0
0
53
307
1.82
3.76
5.4
3.8
4.94
5.11
kpa
0.66
47
296
11
24
4.67
3.76
1.3
1.2
—
—
—
0
0
158
1200
1.47
3.72
4.1
3.3
0.50
0.50
e6/l
0.01
133
913
234
1935
1.41
3.40
2.6
2.5
—
—
—
0
0
7
10
7.08
3.37
1.1
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
9
20
4.56
3.12
1.1
1.2
—
—
—
0
0
11
30
3.73
3.10
1.0
1.0
—
—
—
0
0
23
106
2.23
3.08
1.8
1.4
—
—
—
0
0
25
120
2.14
3.04
2.1
1.6
—
—
—
0
0
15
57
2.68
2.99
1.2
1.3
1760.50
1291.31
e6/l
—
10
39
5
5
10.09
2.98
2.2
8.2
—
—
—
0
0
123
925
1.44
2.97
1.7
1.8
570.41
7570157.17
pmol/l
0.50
95
753
19
83
2.34
2.88
1.9
1.3
—
—
—
0
0
19
83
2.34
2.88
1.9
1.3
—
—
—
0
0
6
9
6.73
2.87
2.3
1.4
—
—
—
0
0
10
28
3.62
2.80
1.7
2.0
—
—
—
0
0
180
1460
1.37
2.79
4.1
3.5
2.32
2.36
mmol/l
3.30
157
1259
101
1337
0.69
2.78
2.8
3.2
6.39
7.31
mmol/l
1.92
86
1100
8
215
0.36
2.74
1.4
1.8
—
—
—
0
0
10
30
3.38
2.61
1.0
1.0
—
—
—
0
0
135
1055
1.39
2.59
4.3
4.2
0.00
0.00
estimate
-0.00
71
320
8
20
4.05
2.57
1.8
1.9
—
—
—
0
0
20
95
2.15
2.52
4.6
1.3
—
—
—
0
0
8
21
3.86
2.47
1.8
1.9
—
—
—
0
0
13
51
2.59
2.46
1.2
1.3
107318.13
59171.34
e6/l
—
8
29
227
1935
1.33
2.46
5.7
5.6
0.00
0.00
estimate
-0.00
77
333
9
27
3.38
2.40
1.8
1.8
—
—
—
0
0
227
1940
1.32
2.39
4.3
4.1
0.00
0.00
estimate
0.50
82
362
20
98
2.09
2.35
1.2
1.2
603.30
533.65
mg/l
0.17
20
92
110
1397
0.72
2.31
3.7
3.9
16.26
8.26
mg/mmol
0.79
73
877
113
873
1.39
2.30
4.3
3.1
2.41
2.46
mmol/l
4.29
98
759
179
1493
1.32
2.20
4.5
4.3
—
—
—
0
0
187
1571
1.31
2.18
4.5
3.3
—
—
—
0
0
62
433
1.50
2.17
3.3
3.5
1.79
2.19
mmol/l
0.34
45
355
11
42
2.66
2.15
1.1
1.1
—
—
—
0
0
227
1963
1.30
2.12
4.2
4.1
0.00
0.01
estimate
0.50
79
322
191
1616
1.30
2.09
2.5
2.2
78.28
78.24
nmol/l
0.01
172
1391
11
43
2.59
2.09
1.1
1.1
—
—
—
0
0
62
437
1.48
2.08
3.3
3.5
5.60
5.82
kpa
0.89
62
425
17
83
2.09
2.03
1.2
1.2
70.08
48.57
e6/l
0.11
12
69
32
195
1.69
1.99
3.6
6.9
2.05
1.53
%
1.53
32
182
48
324
1.54
1.98
3.6
2.8
41.00
60.85
ml/min/173m2
5.23
26
132
14
64
2.22
1.96
1.1
1.1
—
—
—
0
0
5
11
4.58
1.94
1.0
1.2
—
—
—
0
0
6
16
3.78
1.94
1.2
1.1
—
—
—
0
0
6
16
3.78
1.94
2.5
1.1
—
—
—
0
0
8
29
2.79
1.80
1.1
1.1
—
—
—
0
0
6
152
0.39
1.79
1.0
1.0
—
—
—
0
0
22
125
1.80
1.75
1.1
1.3
—
—
—
0
0
11
48
2.32
1.71
1.1
1.5
92.94
65.41
%
—
5
37
38
550
0.66
1.64
10.9
7.8
—
—
—
0
0
10
44
2.30
1.56
1.4
1.3
—
—
—
0
0
14
72
1.97
1.50
1.6
1.4
—
—
—
0
0
111
1330
0.78
1.44
3.4
4.8
22.91
21.13
%
0.66
53
681
156
1338
1.25
1.44
2.3
2.1
82.96
198.54
u/l
8.64
145
1255
402
3826
1.32
1.42
41.9
16.5
19.20
25.40
mg/l
4.86
373
3070
369
3880
0.79
1.39
5.2
5.4
2.16
2.62
mmol/l
20.88
339
3526
5
17
2.96
1.36
2.6
5.9
—
—
—
0
0
8
34
2.38
1.29
1.1
1.1
—
—
—
0
0
103
853
1.26
1.28
4.0
3.9
372.07
289.53
ng/l
0.18
89
716
5
19
2.65
1.22
1.0
1.3
—
—
—
0
0
25
165
1.54
1.20
1.2
2.0
31.71
38.70
u/l
0.73
20
144
14
79
1.80
1.18
1.1
1.1
—
—
—
0
0
69
549
1.30
1.18
8.8
8.2
0.56
1.34
mmol/l
0.61
51
430
0
36
0.00
1.14
0.0
1.2
—
1.64
—
0
20
58
453
1.32
1.13
9.7
9.2
107.02
120.28
g/l
4.67
58
442
11
58
1.92
1.13
3.3
4.1
—
—
—
0
0
7
30
2.35
1.12
1.1
1.1
—
—
—
0
0
7
31
2.28
1.10
1.4
1.2
—
—
—
0
0
5
21
2.40
1.09
1.2
1.2
—
—
—
0
0
73
887
0.79
1.06
3.8
4.4
1.01
1.02
kg/l
1.41
13
129
34
247
1.41
1.05
13.4
10.6
23.38
24.62
mmol/l
0.90
34
242
49
381
1.32
1.00
3.0
2.5
39.29
34.16
u/l
0.37
41
317
79
943
0.81
0.98
2.5
3.2
0.83
0.78
ug/l
0.19
54
666
7
36
1.96
0.97
1.7
2.2
—
—
—
0
0
10
55
1.84
0.92
1.1
1.3
0.63
0.55
nmol/l
—
10
49
44
343
1.31
0.90
2.2
3.7
79.29
82.42
ng/l
0.10
37
300
349
3644
0.84
0.89
5.9
6.6
37.22
40.74
mmol/mol
12.03
324
3356
16
103
1.57
0.88
1.4
1.5
—
—
—
0
0
6
30
2.01
0.87
1.3
1.2
—
—
—
0
0
6
30
2.01
0.87
1.3
1.2
—
—
—
0
0
6
30
2.01
0.87
1.3
1.2
—
—
—
0
0
6
30
2.01
0.87
1.3
1.2
—
—
—
0
0
6
30
2.01
0.87
1.3
1.2
—
—
—
0
0
364
3785
0.84
0.87
4.8
4.8
3.85
4.51
mmol/l
26.13
333
3464
365
3793
0.84
0.85
5.4
5.1
5.99
6.08
mmol/l
0.65
322
3417
15
96
1.58
0.85
1.3
1.6
—
—
—
0
0
37
284
1.33
0.85
1.8
1.4
—
—
—
0
0
304
2871
1.16
0.84
4.4
3.8
15.22
14.97
pmol/l
0.91
282
2538
254
2377
1.15
0.77
4.6
3.2
88.69
54.12
u/l
3.33
242
2186
5
24
2.09
0.74
1.0
1.0
—
—
—
0
0
15
101
1.50
0.71
3.0
3.3
0.75
0.81
nmol/l
—
8
79
14
93
1.52
0.70
1.1
1.3
—
—
—
0
0
363
3755
0.86
0.69
4.8
4.7
1.15
1.46
mmol/l
29.45
332
3406
151
1652
0.87
0.68
4.4
5.4
3.36
2.78
ug/l
0.30
142
1468
7
43
1.64
0.67
1.1
1.1
—
—
—
0
0
16
113
1.43
0.62
1.3
2.0
—
—
—
0
0
38
309
1.25
0.60
5.1
7.4
22.95
24.54
mmol/l
1.44
38
292
0
21
0.00
0.60
0.0
1.1
—
297.62
—
0
13
0
22
0.00
0.59
0.0
2.5
—
—
—
0
0
0
22
0.00
0.59
0.0
2.5
—
—
—
0
0
50
589
0.83
0.58
1.3
1.3
14.56
16.52
u/ml
0.05
18
215
24
187
1.30
0.54
2.7
3.3
1.40
1.37
mmol/l
0.05
24
182
11
158
0.69
0.53
1.4
1.7
—
—
—
0
0
13
176
0.73
0.47
1.3
1.8
—
—
—
0
0
16
122
1.32
0.43
1.4
1.2
—
—
—
0
0
16
122
1.32
0.43
1.4
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
55
621
0.87
0.41
1.3
1.3
24.85
39.90
iu/ml
1.04
26
199
43
494
0.86
0.40
3.6
4.2
3.09
39.36
ug/l
1.47
28
415
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
9
66
1.37
0.38
1.6
1.1
—
—
—
0
0
5
36
1.39
0.38
1.8
2.9
23.72
61.95
u/ml
—
5
36
15
191
0.78
0.37
1.3
1.2
155.00
157.61
iu/ml
—
6
71
15
191
0.78
0.37
3.5
3.8
14.60
1340.84
u/ml
1.01
15
168
411
4175
0.89
0.36
66.0
24.2
115.29
134.12
g/l
59.21
404
4100
5
80
0.62
0.35
2.8
1.7
—
—
—
0
0
411
4174
0.89
0.35
65.6
24.1
12.56
6.78
e9/l
10.17
401
4050
411
4174
0.89
0.35
65.5
24.1
3.96
4.44
e12/l
22.84
402
4048
39
446
0.86
0.35
2.4
2.5
6.35
6.91
ug/l
0.12
31
393
79
722
1.11
0.35
4.2
3.1
1.16
2.04
e6/l
0.83
41
411
411
4173
0.89
0.34
65.7
24.1
314.37
239.71
e9/l
12.57
404
4062
411
4173
0.89
0.34
65.8
24.3
35.79
39.79
%
21.84
380
3871
359
3512
1.09
0.33
5.3
4.7
2.30
2.01
mu/l
2.52
336
3141
42
371
1.14
0.32
3.4
2.7
4.11
4.40
kpa
0.46
42
358
31
354
0.87
0.28
1.3
1.8
1.82
1.62
%
0.49
24
296
8
64
1.25
0.27
1.8
1.8
213.63
229.40
pmol/l
—
8
57
51
464
1.11
0.26
1.5
1.4
—
—
—
0
0
101
1072
0.93
0.26
1.8
1.6
1.69
1.31
mmol/l
3.15
89
885
9
74
1.22
0.25
1.1
1.2
—
49.03
—
0
6
25
218
1.15
0.24
1.8
1.4
45.20
51.18
au/ml
—
5
20
7
94
0.74
0.22
1.0
1.1
—
9.83
—
0
9
0
12
0.00
0.21
0.0
2.1
—
2.76
—
0
5
6
49
1.23
0.20
1.3
1.6
—
—
—
0
0
6
49
1.23
0.20
1.7
1.3
—
—
—
0
0
9
80
1.13
0.15
1.1
1.2
—
1.13
—
0
6
80
766
1.05
0.13
4.2
2.9
0.84
1.11
e6/l
0.61
45
451
52
544
0.95
0.10
4.4
4.8
28.00
32.18
%
1.95
40
361
406
4035
1.04
0.09
41.5
19.8
138.98
139.60
mmol/l
3.57
398
3924
5
62
0.80
0.08
1.0
1.9
—
—
—
0
0
37
388
0.95
0.07
1.3
1.4
—
—
—
0
0
79
768
1.03
0.07
1.2
1.2
7.17
1.49
u/ml
0.41
12
197
8
76
1.05
0.07
1.3
1.3
—
—
—
0
0
9
87
1.04
0.07
1.1
1.2
—
—
—
0
0
408
4060
1.03
0.07
32.5
11.2
25.16
25.14
u/l
0.01
397
3900
362
3642
0.98
0.06
4.8
4.3
1.45
1.27
mmol/l
3.95
329
3283
406
4041
1.03
0.06
44.0
19.9
4.09
4.00
mmol/l
8.24
396
3930
365
3629
1.02
0.06
36.7
15.5
72.17
75.15
ml/min/173m2
2.08
328
2991
26
247
1.06
0.05
3.5
2.5
6.52
15.21
au/ml
—
5
15
10
90
1.11
0.05
1.6
1.8
43.30
45.95
nmol/l
—
10
83
10
92
1.09
0.03
1.1
1.3
—
3.12
—
0
15
10
94
1.07
0.01
1.1
1.3
—
2.44
—
0
16
17
165
1.03
0.00
1.4
1.3
—
—
—
0
0
16
162
0.99
0.00
2.3
3.3
16.59
61.07
u/ml
1.11
16
154
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
0.00
0.0
12.3
—
6.69
—
0
7
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
8.16
—
0
7
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.5
—
96.52
—
0
6
5
51
0.98
-0.00
1.0
1.8
—
—
—
0
0
5
49
1.02
-0.00
1.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CHRONMYELOPRO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHRONMYELOPRO | 4.416 [3.64, 5.36] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.395 |
During the follow-up period (1.1.1998 — 31.12.2019), 638 out of 1093 females with CHRONMYELOPRO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHRONMYELOPRO | 4.304 [3.38, 5.49] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.008 |
During the follow-up period (1.1.1998 — 31.12.2019), 708 out of 1119 males with CHRONMYELOPRO died.
Mortality risk
Mortality risk for people of age
years, who have CHRONMYELOPRO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.402% | 0.735% |
| 5 | 2.414% | 4.819% |
| 10 | 6.333% | 12.442% |
| 15 | 12.699% | 21.902% |
| 20 | 20.929% | 35.833% |
Relationships between endpoints
↥Index endpoint: CHRONMYELOPRO – Chronic myeloproliferative disease
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data